Cancer Cachexia Market is segmented By Therapeutics (Corticosteroids, Cannabinoids (Dronabinol), Anabolic Steriods, Cytokine Inhibitors, Others), By Mechanism (Appetite Stimulators, Weight Loss Stabilizers, Others), By Distribution Channel (Hospital Stores, Retail Pharmacy Stores, Online Pharmacy), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031
Cancer Cachexia Market Overview
Cancer cachexia market size was valued at US$ YY million in 2023 and is estimated to reach US$ YY million by 2031, growing at a CAGR of 6.8% during the forecast period 2024-2031. Cancer cachexia is a wasting illness in which weight loss, anorexia, asthenia, and anemia are all symptoms.
Due to a complicated interaction between tumor and host variables, the pathogenicity of this condition is multifactorial. Cachexia's signs and symptoms are used as prognostic indicators in cancer patients. Due to a complicated interaction between tumor and host variables, the pathogenicity of this condition is multifactorial. Drugs for cancer cachexia are used to treat or relieve the condition.
Cancer Cachexia Market Scope
|
Metrics |
Details |
|
Market CAGR |
6.8% |
|
Segments Covered |
By Therapeutics, By Mechanism, By Distributional Channels, and By Region |
|
Report Insights Covered |
Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights. |
|
Fastest Growing Region |
Asia Pacific |
|
Largest Market Share |
North America |
For More Insights Request Free Sample
Cancer Cachexia Market Dynamics
The global cancer cachexia market growth is driven by the expansion in the prevalence of serious health conditions, for instance, cancer, and the rising number of cachexia among these patients. This is additionally supported by the growing cognizance amongst people about the convenience of novel therapeutic drugs to treat cancer cachexia.
Most big firms are concentrating their R&D efforts on developing highly effective new medications for cancer cachexia treatment. As a result of this aspect, the number of medicines in the pipeline awaiting approval and commercial launch has increased. According to clinicaltrials.gov, 141 studies have been completed or are in the process of discovering medications to treat cancer cachexia until February 7, 2022.
Cachexia therapy options for cancer patients are now limited to medications such as progestogens, corticosteroids, and others. Although there is a clinical gap in the treatment outcomes, these medications have proven their efficacy in treating cancer-induced cachexia. There is currently no medication candidate that has been approved, particularly for treating this illness. This widens the treatment gap, which market players hope to close through research and development and the launch of new pharmaceuticals into the worldwide market.
For instance, Pfizer Inc.'s PF-06946860 is now in Phase 1 of clinical testing. The experiment aims to see if PF-06946860 can help individuals with cachexia who have non-small cell lung cancer (NSCLC). The success of new candidate clinical trials, regulatory clearances, and drug introductions are expected to increase healthcare professionals' demand and adoption of cancer cachexia therapies.
Huge expenses related to treatment and strict government rules and regulations to limit growth will hinder the market growth.
Despite the increased global prevalence of cancer cachexia, various issues hamper the overall market's growth. The high expense of cancer and its supportive therapy, as well as limited reimbursement for therapies in emerging countries, are among them. The cost of treating cancer patients with cachexia is expected to be higher than that of cancer patients who do not have cachexia. Furthermore, one of the biggest impediments to the development and licensing of an effective treatment for this condition has been the government's strict restrictions regulating the clinical trial of new candidates. As a result, the increased out-of-pocket costs associated with cancer-induced cachexia and the absence of approved treatment options are likely to contribute to the market's slow expansion throughout the forecast period.
COVID-19 Impact on Cancer Cachexia Market
The COVID-19 pandemic influenced the cancer cachexia market, as hospitals and healthcare facilities drastically decreased due to global social distancing measures. The COVID-19 pandemic had a tremendous influence on the global economy and general hospital care for non-COVID-19 patients in hospitals around the world.
Changes in nutritional status and weight loss after hospitalization are widely reported in some groups, according to a study published in the British Journal of Nutrition in 2020. However, it has not been well investigated in COVID-19 patients. COVID-19 symptoms and associated diseases, on the other hand, degrade nutritional status, resulting in cachexia. Cancer patients are more likely to become infected with COVID-19 because they are immunocompromised and have a lower ability to fight infection than healthy people. In addition, if a cancer patient contracts COVID-19, they are more likely to suffer organ-related problems or cachexia.
Cancer Cachexia Market Segment Analysis
The segment in the market, appetite stimulators is projected to produce at the highest CAGR during the forecast period 2022-2029.
Loss of appetite and weight loss are common among cancer patients. In cancer patients, unintentional weight loss and anorexia (a lack of appetite or desire to eat) is linked to lower performance status, a lower response and tolerance to therapy, a lower survival rate, and a lower quality of life. As a result, patients with a diminished appetite may want to consider increasing their intake of an appetite stimulant. One of the primary factors driving the overall market's growth is the rising prevalence of cancer cachexia instances.
Appetite stimulants like dexamethasone, methylprednisolone, prednisolone, megestrol acetate, and medroxyprogesterone acetate have been demonstrated to boost appetite and weight in cancer cachexia patients, according to the Oncology Nursing Society. Megestrol acetate is an appetite stimulant with antigonadotropic and progestational properties. Megestrol acetate has been shown to improve hunger and cause a modest weight gain in cancer patients who are losing weight. It hasn't increased lean body mass or quality of life, though. As a result, demand will likely rise as the number of cancer diagnoses rises.
As a result of the growing global burden of cancer, industry players are gradually spending on innovative products and R&D, boosting market growth. For instance, Pfizer Inc., a multinational pharmaceutical company, began a global 12-week open-label research in March 2020 to see how well their medicine, PF-06946860, is tolerated in patients with cancer cachexia. As a result, such variables may assist the appetite stimulators category in driving market expansion
Cancer Cachexia Market Geographical Share
North America region holds the largest market share of the global cancer cachexia market
North America dominates the market for cancer cachexia. It is expected to show a similar trend over the forecast period, owing to the presence of many drug makers and the changing paradigm of cancer patient care. According to GLOBOCAN 2020, Mexico has around 195,499 new cancer cases. At the same time, in Mexico, around 90,222 cancer-related deaths will be expected in 2020.
According to Markus S. Anker's article "Orphan Disease Status of Cancer Cachexia in the United States and the European Union: A Systematic Review," published in 2019, the prevalence of cancer cachexia in the United States ranged between 11,300 (0.4/10 000, gastric cancer) and 92,000 patients (2.9/10000, lung cancer) in the 14 separately analyzed cancer types.
The development of the cancer cachexia market in the region has also been aided by advances in novel technology for treating cancer cachexia and a robust product pipeline for wasting syndrome. AV-380, a first-in-class, powerful, and humanized inhibitory antibody targeting GDF15 was developed by Aveo Oncology, a biopharmaceutical company based in the United States, to treat cancer cachexia. The product is on pace to be submitted for an IND, with a Phase 1 clinical trial starting in Q1 2021. As a result of these factors, the market in the region is predicted to develop in the region.
Cancer Cachexia Companies and Competitive Landscape
The cancer cachexia market is a moderately competitive presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include Aeterna Zentaris, Aphios Corporation, Bristol-Myers Squibb Company, Pfizer Inc., Helsinn Group, Merck KgaA, Artelo Biosciences Inc., NGM Biopharmaceuticals, Aveo Oncology, Aavogen Inc. among others. The significant players are implementing numerous growth strategies such as acquisitions, collaborations, and product launches, which are contributing to the growth of the cancer Cachexia Market globally. For instance, in February 2021, Artelo Biosciences Inc. collaborated with researchers from Trinity College Dublin to investigate pre-clinical models of human cancer cachexia.
Bristol-Myers Squibb Company
Overview:
The Bristol-Myers Squibb Company is a global biopharmaceutical company that discovers, develops, licenses manufactures, and markets biopharmaceutical products. Hematology, cancer, cardiovascular, immunology, fibrotic, neurology, and covid-19 disorders are all treated with their medications.
Product Portfolio:
Megace: Megestrol acetate, a synthetic by-product of the steroid hormone progesterone, is found in MEGACE (megestrol acetate, USP) Oral Suspension. MEGACE Oral Suspension is a liquid that contains 40 mg of micronized megestrol acetate per milliliter.
The global cancer cachexia market report would provide access to approximately 40+ market data tables, 45+ figures, and in the range of 195 (approximate) pages.
